UroGen Pharma Ltd. Forecast, price target & analysts
UroGen Pharma Ltd. Target price 2025 - Analyst rating & recommendation
UroGen Pharma Ltd. Classifications & Recommendation:
UroGen Pharma Ltd. Price Target
| Target Price | $36.71 |
| Price | $9.29 |
| Potential |
295.20%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target UroGen Pharma Ltd. 2026 .
The average UroGen Pharma Ltd. target price is $36.71.
This is
295.20%
register free of charge
$64.00
588.91%
register free of charge
$22.00
136.81%
register free of charge
|
|
| A rating was issued by 7 analysts: 6 Analysts recommend UroGen Pharma Ltd. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the UroGen Pharma Ltd. stock has an average upside potential 2026 of
295.20%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 82.71 | 91.00 |
| 28.51% | 10.02% | |
| EBITDA Margin | -77.17% | -104.49% |
| 35.68% | 35.40% | |
| Net Margin | -181.08% | -146.51% |
| 42.57% | 19.09% |
7 Analysts have issued a sales forecast UroGen Pharma Ltd. 2024 . The average UroGen Pharma Ltd. sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast UroGen Pharma Ltd. 2024 . The average UroGen Pharma Ltd. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 UroGen Pharma Ltd. Analysts have issued a net profit forecast 2024. The average UroGen Pharma Ltd. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.55 | -3.16 |
| 26.20% | 10.99% | |
| P/E | negative | |
| EV/Sales | 2.90 |
4 Analysts have issued a UroGen Pharma Ltd. forecast for earnings per share. The average UroGen Pharma Ltd. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the UroGen Pharma Ltd. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
UroGen Pharma Ltd....
Current UroGen Pharma Ltd. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Feb 25 2025 |
| D. Boral Capital | Locked ➜ Locked | Locked | Feb 20 2025 |
| D. Boral Capital | Locked ➜ Locked | Locked | Feb 18 2025 |
| D. Boral Capital | Locked ➜ Locked | Locked | Feb 12 2025 |
| D. Boral Capital | Locked ➜ Locked | Locked | Jan 23 2025 |
| D. Boral Capital | Locked ➜ Locked | Locked | Jan 15 2025 |
| D. Boral Capital | Locked ➜ Locked | Locked | Dec 06 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Feb 25 2025 |
|
Locked
D. Boral Capital: Locked ➜ Locked
|
Feb 20 2025 |
|
Locked
D. Boral Capital: Locked ➜ Locked
|
Feb 18 2025 |
|
Locked
D. Boral Capital: Locked ➜ Locked
|
Feb 12 2025 |
|
Locked
D. Boral Capital: Locked ➜ Locked
|
Jan 23 2025 |
|
Locked
D. Boral Capital: Locked ➜ Locked
|
Jan 15 2025 |
|
Locked
D. Boral Capital: Locked ➜ Locked
|
Dec 06 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
